Back to Browse Journals » Vascular Health and Risk Management » Volume 6

Atherogenic dyslipidemia and diabetes mellitus: what’s new in the management arena?

Authors Ajoy Kumar, Vibhuti Singh

Published Date July 2010 Volume 2010:6 Pages 665—669

DOI http://dx.doi.org/10.2147/VHRM.S5686

Published 30 July 2010

Ajoy Kumar1, Vibhuti Singh2

1Bayfront Family Medicine Residency, St Petersburg FL, USA; 2University of South Florida College of Medicine and Suncoast Cardiovascular Center, St Petersburg, FL, USA

Abstract: When compared with the general population, the diabetic population is at higher risk of cardiovascular disease (CVD), as predicted by the Framingham Risk Score calculations (10-year risk 20%). For this reason diabetes is considered a “coronary disease equivalent” condition, as classified by the National Cholesterol Education Program Adult Treatment Panel (NCEP-ATP) III. Furthermore, patients with diabetes who experience a myocar­dial infarction have a poorer prognosis than non­diabetic patients, which contributes to their overall higher mortality. Dyslipidemia is a major underlying risk factor contributing to the excess CVD risk, and is usually more atherogenic in the presence of diabetes. It is uniquely manifested by raised levels of triglycer­ides, low levels of high-density lipoprotein cholesterol, and smaller, denser, and more atherogenic low-density lipoprotein particles. Recent trials have suggested the need for more aggressive treatment of dyslipidemia in this subpopulation than the current recommendations by the NCEP-ATP III. This review addresses the newer developments in the diabetes arena in terms of our current understanding of atherogenic dyslipidemia in diabetes and data from the latest randomized trials addressing its management.

Keywords: atherogenic dyslipidemia, diabetes mellitus

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Readers of this article also read:

Disruption of human papillomavirus 16 E6 gene by clustered regularly interspaced short palindromic repeat/Cas system in human cervical cancer cells [Corrigendum]

Yu L, Wang XL, Zhu D, Ding WC, Wang LM, Zhang CL, Jiang XH, Shen H, Liao SJ, Ma D, Hu Z, Wang H

OncoTargets and Therapy 2015, 8:365-366

Published Date: 4 February 2015

Racial differences in tumor necrosis factor-α-induced endothelial microparticles and interleukin-6 production

Brown MD, Feairheller DL, Thakkar S, Veerabhadrappa P, Park JY

Vascular Health and Risk Management 2011, 7:541-550

Published Date: 26 August 2011

Increased reactive oxygen metabolites is associated with cardiovascular risk factors and vascular endothelial damage in middle-aged Japanese subjects

Sugiura T, Dohi Y, Takase H, Yamashita S, Tanaka S, Kimura G

Vascular Health and Risk Management 2011, 7:475-482

Published Date: 19 July 2011

Novel drug-eluting stents in the treatment of de novo coronary lesions

Davide Capodanno, Fabio Dipasqua, Corrado Tamburino

Vascular Health and Risk Management 2011, 7:103-118

Published Date: 25 February 2011

Relationship between natriuretic peptides and echocardiography parameters in patients with poorly regulated type 2 diabetes

Magnus Dencker, Martin Stagmo, Mozhgan Dorkhan

Vascular Health and Risk Management 2010, 6:373-382

Published Date: 18 May 2010

On the antiatherogenic effects of vitamin E: the search for the Holy Grail

Francesco Galli, Dimitrios Kirmizis, Dimitrios Chatzidimitriou

Vascular Health and Risk Management 2010, 6:69-71

Published Date: 16 February 2010

Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors

Eduardo Pimenta, Suzanne Oparil

Vascular Health and Risk Management 2009, 5:453-463

Published Date: 19 May 2009